The first quarter of 2024 saw 115 agreed research and development partnerships totaling $36 billion. Eight of the top ten ranked by deal value involved technology platforms for developing a broad range of therapeutics, and three included Novartis as it expands its RNA and gene-based programs.

The coronavirus disease 2019 pandemic emphasized the crucial role of vaccines in protecting public health and led to record-breaking sales for vaccine developers. Recent deals highlight a shifting focus towards other infectious disease threats.

For centuries, women’s health has been neglected across science, medicine and technology. A new report from the World Economic Forum suggests tackling this could unlock a $1 trillion economic boost with the potential to change the lives of 3.9 billion women.

Major biopharma companies are setting up partnerships with companies that are pioneering the application of artificial intelligence tools to develop therapeutic antibodies.

Innoviva Specialty Therapeutics is filling the gap in high-mortality infectious diseases and critical care issues with innovative, category-leading products.

MimiVax, Inc. is developing immunotherapeutic vaccines and targeted therapies for treating cancers and preventing recurrence. The company’s lead agent, SurVaxM, targets survivin, a cell-survival protein expressed in cancer cells.

Primrose Bio’s advanced technology for manufacturing nucleic acids and proteins makes it the partner of choice for pharma companies developing new vaccines, therapeutics and bio-based products.

By coupling its expertise, scale, and technologies with those of like-minded biopharma partners GSK is striving to make a real difference for patients.

Screening and diagnostics based on the detection of cancer-generated cellular biomarkers.

Pylum Biosciences has built a technology platform to create antibacterials that target individual strains of bacteria without affecting the microbiota. Its lead preclinical programs target Clostridioides difficile for infectious disease and Fusobacterium nucleatum for colorectal cancer.

Engineering antibody constant region platforms to enhance convenience and efficacy of antibody therapeutics.

GSK welcomes collaborations to advance early- or late-stage vaccine-development projects and get ahead of disease together.

Cancer Research Horizons (CRH) is harnessing the skills, expertise, and research network of its parent organization to speed-up the discovery and development of transformative oncology drugs, improve patient outcomes, and advance assets for biopharma partners.